RADX FY2026 EPS Boosted by Brookline Capital Management

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) – Stock analysts at Brookline Capital Management lifted their FY2026 earnings estimates for Radiopharm Theranostics in a research report issued on Wednesday, October 22nd. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings of ($2.25) per share for the year, up from their prior estimate of ($4.81). Brookline Capital Management has a “Buy” rating and a $18.00 price target on the stock. Brookline Capital Management also issued estimates for Radiopharm Theranostics’ FY2027 earnings at ($2.38) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $15.00.

Radiopharm Theranostics Stock Down 0.2%

Shares of RADX opened at $5.27 on Monday. The company’s 50 day moving average price is $6.14 and its 200 day moving average price is $5.10. Radiopharm Theranostics has a 52 week low of $3.50 and a 52 week high of $50.82.

Hedge Funds Weigh In On Radiopharm Theranostics

An institutional investor recently bought a new position in Radiopharm Theranostics stock. PNC Financial Services Group Inc. bought a new stake in shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 8,000 shares of the company’s stock, valued at approximately $37,000. PNC Financial Services Group Inc. owned about 0.10% of Radiopharm Theranostics at the end of the most recent reporting period.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.